moxifloxacin has been researched along with enoxacin in 10 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (enoxacin) | Trials (enoxacin) | Recent Studies (post-2010) (enoxacin) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 734 | 74 | 122 |
| Protein | Taxonomy | moxifloxacin (IC50) | enoxacin (IC50) |
|---|---|---|---|
| V-type proton ATPase subunit B, brain isoform | Homo sapiens (human) | 10 | |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Mayer, C | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ciura, K; Fallarero, A; Fedorowicz, J; Gilbert-Girard, S; Konopacka, A; Lejnowski, D; Morawska, M; Sączewski, J; Savijoki, K; Skok, Ž; Tomašič, T; Waleron, K | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Holzgrabe, U; Kiefer, W; Neugebauer, U; Popp, J; Schmitt, M; Szeghalmi, A | 1 |
| Depta, JP; Pichler, WJ; Schmid, DA | 1 |
| Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N | 1 |
| Beare, PA; Bloom, ME; Broeckel, RM; Flather, DP; Kendall, BL; Morris, CN; Offerdahl, DK; Scroggs, SLP | 1 |
1 review(s) available for moxifloxacin and enoxacin
| Article | Year |
|---|---|
Quinolone antibiotics.
Topics: | 2019 |
9 other study(ies) available for moxifloxacin and enoxacin
| Article | Year |
|---|---|
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
Topics: Amino Acid Sequence; Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Molecular Sequence Data; Mutagenesis, Site-Directed; Mycobacterium tuberculosis; Protein Structure, Secondary; Quinolones; Sequence Homology, Amino Acid; Structure-Activity Relationship | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; HEK293 Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Quaternary Ammonium Compounds; Quinolones; Structure-Activity Relationship | 2019 |
Vibrational spectroscopic characterization of fluoroquinolones.
Topics: Aza Compounds; Cinoxacin; Ciprofloxacin; DNA Gyrase; DNA, Bacterial; Enoxacin; Enzyme Inhibitors; Fluoroquinolones; Hydrogen Bonding; Hydrogen-Ion Concentration; Models, Chemical; Models, Molecular; Models, Theoretical; Moxifloxacin; Nalidixic Acid; Norfloxacin; Ofloxacin; Oxolinic Acid; Quinolines; Quinolones; Spectrophotometry, Infrared; Spectrum Analysis, Raman; Temperature; Ultraviolet Rays; Vibration; Water | 2005 |
T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antigen-Presenting Cells; Aza Compounds; Cell Proliferation; Cells, Cultured; Ciprofloxacin; Clone Cells; Cross Reactions; Drug Hypersensitivity; Enoxacin; Female; Fluoroquinolones; Humans; Hypersensitivity, Delayed; Middle Aged; Moxifloxacin; Nalidixic Acid; Norfloxacin; Ofloxacin; Patch Tests; Pipemidic Acid; Quinolines; Quinolones; T-Lymphocytes | 2006 |
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
Topics: Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Enoxacin; Fluoroquinolones; Gatifloxacin; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2010 |
Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV.
Topics: A549 Cells; Angiotensin-Converting Enzyme 2; Animals; Anti-Bacterial Agents; Antiviral Agents; Cell Line; Chlorocebus aethiops; Ciprofloxacin; Coronavirus Infections; COVID-19 Drug Treatment; Enoxacin; Fluoroquinolones; Humans; Levofloxacin; Middle East Respiratory Syndrome Coronavirus; Moxifloxacin; SARS-CoV-2; Vero Cells | 2020 |